Accelerate to discover

Back to filter

Related topics

Advances in Leukemia research using shear flow and Bioflux system

Fluxion Biosciences

Feb 3, 2023

Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...

Webinar: Dose Reduction and Image Enhancement in Preclinical Mouse Imaging using Deep Learning

MOLECUBES

Jan 31, 2023

In this webinar, ir. Florence Muller (Ghent University - University of Pennsylvania) is presenting two recent studies...

ACCELA Educational webinar series: Unlocking Spatial Biology with RareCyte Orion Technology

RareCyte

Nov 16, 2022

Discover full slide, high-plex biomarker quantitation with the all-in-one spatial biology...

Practical aspects of an imaging study: live in vivo scanning

MOLECUBES

Nov 11, 2022

In this webinar, MOLECUBES will present a live in vivo demonstration, showing the entire workflow from animal...

Feb 4, 2023

Advances in Leukemia research using shear flow and Bioflux system

Fluxion Biosciences

May 24, 2022

Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...

In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers

MOLECUBES

Mar 9, 2022

Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...

Feb 4, 2023

Show all topics (10)

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

Aug 21, 2017

September 7, 2017, 7 pm CEST

Chia-Wei Li, PhD, The University of Texas M. D. Anderson Cancer Center 

Here we reveal PD-L1’s immunosuppression activity is stringently modulated by the spatial restraints between ubiquitination and N-linked glycosylation. We identified GSK3beta as a novel PD-L1 interacting protein capable of inducing phosphorylation dependent proteasome degradation. The essence of PD-L1 N192, N200 and N219 glycosylation suggests it antagonizes GSK3beta binding. In this regard, only non-glycosylated PD-L1 forms a complex with GSK3beta and beta-TrCP. More importantly, activation of GSK3beta-mediated PD-L1 degradation by TKI can reduce membrane PD-L1 expression and thereby enhance anti-tumor immunity. To test T cell-mediated cancer cell killing in vitro, we employed a time lapse microscopy, IncuCyte, to monitor RFP-tagged BT549 cells and activated PBMC interaction over a five day period. Massive cancer cell death was observed in glycosylation deficient cancer cells, suggesting glycosylation of PD-L1 is required for its immunosuppression. Together, our results link ubiquitination and glycosylation pathways with stringent regulation of PD-L1, proposing a new therapeutic strategy to enhance cancer immune therapy efficacy.

Learning objectives:

  • Molecular mechanism of PD-L1 regulation in cancer cells
  • Immunosuppressive nature of triple negative breast cancer
  • Using in vitro co-culture system to analyze T cell-mediated cancer cell killing effect

Register now

Webinar

Get more info

Riccardo Pasculli

Head of application support

Riccardo

Pasculli

+420 731 127 717

Send Message

Brand profile

Sartorius & Essen BioScience

Essen BioScience & Sartorius is a team of engineers and biologists with deep expertise in cell-based assays and biomolecular interaction analysis. They invent, manufacture, supply and support instrumentation, reagents and protocols.

Related products

High throughput, real-time and automated measurements of live-cell activity, inside your incubator

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey